MONMOUTH JUNCTION, NJ–(Marketwired – November 17, 2014) – DiamiR Biosciences, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the company’s Chief Executive Officer, Dr. Kira Sheinerman, will participate in the 7th annual Clinical Trials on Alzheimer’s Disease in Philadelphia, PA and will present data on analysis of circulating brain-enriched microRNAs for detection and differentiation of Mild Cognitive Impairment, Alzheimer’s and Parkinson’s diseases.